Clinical Trial Update: A Study of IMR-687 in Adult Participants With Sickle Cell Anemia (Homozygous HbSS or Sickle-β0 Thalassemia) [Phase 2]

View source ↗

Summary

Phase 2 trial of IMR-687 in adults with sickle cell disease (HbSS or Sickle-β0 thalassemia) has completed and results were posted on 2022-04-14.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sickle Cell Disease

Drugs mentioned

• IMR-687

Snippet

Sponsor: Cardurion Pharmaceuticals, Inc. | Conditions: Sickle Cell Disease | Phase 2 | Status: COMPLETED | Results posted: 2022-04-14